{"schema_version":"1.0","type":"article","title":"藥王的最佳搭檔？療效翻倍！","url":"https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.md","lang":"zh-Hant","date":"2026-05-30","publish_at":"2026-05-30T10:30:00+08:00","updated_at":"2026-05-30","category":"商業分析系列","topic":"臨床與 CMC","tags":["Keytruda","INBRX-106","OX40","腫瘤免疫","聯合治療"],"summary":"Keytruda 專利懸崖前，下一代聯合治療能否提高療效天花板與延長生命週期，是藥王商業價值的關鍵問題。","key_points":[],"facts":[],"sections":["Keytruda 的下一個最佳搭檔？INBRX-106 讓 OX40 重新回到腫瘤免疫牌桌","01｜OX40 不是新靶點，但一直是難做的靶點","02｜ INBRX-106 的六價設計，為什麼和過去 OX40 不一樣？","03｜為什麼選 1L R/M HNSCC？因為這是一個很會驗證 PD-1 增益的場景","04｜ 它真的會是 Keytruda 最佳搭檔嗎？現在還不能下結論，但訊號值得重視","05｜ 和 Petosemtamab 相比，INBRX-106 不是最強表觀數據，但可能有更大外推空間","06｜INBRX-109 打底：Inhibrx 不只有 OX40，還有一個接近申請階段的 DR5 資產","07｜為什麼 Inhibrx 可能成為併購標的？因為它剛好踩中大型藥廠的三個焦慮","08｜風險不能忽略：INBRX-106 還在早期，OX40 的死亡谷也還沒完全走完","結語｜INBRX-106 的價值，不只是頭頸癌反應率翻倍，而是 OX40 重新活過來了"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline - MSD","source":"","date":"","url":""},{"title":"Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and N","source":"","date":"","url":""},{"title":"www.msd.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy - May 11, 2026","source":"","date":"","url":""},{"title":"Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab...","source":"","date":"","url":""},{"title":"inhibrxbiosciences.investorroom.com","source":"","date":"","url":""},{"title":"\"Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy - May 11, 2026\"","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"FDA Approves Pembrolizumab for the First-Line Treatment of HNSCC - The ASCO Post","source":"","date":"","url":""},{"title":"https://ascopost.com/issues/june-25-2019/fda-approves-pembrolizumab-for-the-first-line-treatment-of-hnscc/","source":"","date":"","url":"https://ascopost.com/issues/june-25-2019/fda-approves-pembrolizumab-for-the-first-line-treatment-of-hnscc/"},{"title":"ascopost.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/","source":"","date":"","url":"https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"www.sec.gov","source":"","date":"","url":""},{"title":"https://www.sec.gov/Archives/edgar/data/1434265/000094787125000868/ss5386579_exa5a.htm","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1434265/000094787125000868/ss5386579_exa5a.htm"},{"title":"www.sec.gov","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：藥王的最佳搭檔？療效翻倍！","url":"https://drugnews.com.tw/assets/articles/drug-combination-efficacy-doubling/dcard-01.webp"},{"alt":"Dcard 原圖：藥王的最佳搭檔？療效翻倍！","url":"https://drugnews.com.tw/assets/articles/drug-combination-efficacy-doubling/dcard-02.png"},{"alt":"Dcard 原圖：藥王的最佳搭檔？療效翻倍！","url":"https://drugnews.com.tw/assets/articles/drug-combination-efficacy-doubling/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/drug-combination-efficacy-doubling/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-30）。藥王的最佳搭檔？療效翻倍！。https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-30-drug-combination-efficacy-doubling-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}